The effect of COVID-19 on nuclear medicine and radiopharmacy activities: A global survey.

Publication date: Jun 28, 2023

Globally, COVID-19 affected radiopharmaceutical laboratories. This study sought to determine the economic, service, and research impacts of COVID-19 on radiopharmacy. This online survey was conducted with the participation of employees from nuclear medicine and radiopharmaceutical companies. The socioeconomic status of the individuals was collected. The study was participated by 145 medical professionals from 25 different countries. From this work, it is evident that 2-deoxy-2-[18F]fluoro-D-glucose (2-[F]FDG), and Tc-labeled macro aggregated albumin Tc-MAA were necessary radiopharmaceuticals used by 57% (83/145and 34% (49/145;) respondents, respectively for determining how COVID infections affect a patient’s body. The normal scheduling procedure for the radiopharmacy laboratory was reduced by more than half (65%; 94/145). In COVID-19, 70% (102/145) of respondents followed the regulations established by the local departments. Throughout the pandemic, there was a 97% (141/145) decrease in all staffing recruitment efforts. The field of nuclear medicine research, as well as the radiopharmaceutical industry, were both adversely affected by COVID-19.

Open Access PDF

Concepts Keywords
145and Activities
Glucose Affected
Pandemic Covid
Radiopharmaceutical Determine
Socioeconomic Economic


Type Source Name
disease MESH COVID-19
drug DRUGBANK D-glucose
disease MESH infections
drug DRUGBANK Coenzyme M
drug DRUGBANK Dextrose unspecified form
disease MESH influenza
disease MESH lifestyle
disease MESH uncertainty
disease IDO infection
drug DRUGBANK Trestolone
disease VO USA
drug DRUGBANK Etoperidone
disease VO protocol
disease IDO production
disease VO population
disease IDO process
disease VO viable
pathway REACTOME Glucose metabolism
disease VO effective
disease MESH complications
disease VO frequency
disease MESH sore throat
disease VO Imovax ID
disease VO organization
disease VO efficient
disease IDO quality
drug DRUGBANK Spinosad
disease VO time
disease MESH Obstructive sleep apnea
disease MESH pneumonia
disease MESH inflammation
disease MESH cancer
disease MESH interstitial pneumonia
disease VO vaccination
disease MESH pulmonary embolism
disease MESH contraindications
drug DRUGBANK Iodine
disease MESH cardiovascular diseases
drug DRUGBANK Medical air

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *